A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab

Autoimmunity Reviews

Volumn 14, Issue 4, 2015, Pages 323-331

  Ahmed, A Razzaque ^a   Shetty, Shawn ^a  

^a Center for Blistering Diseases   (United States)

Author keywords

Clinical outcomes; Lymphoma; Pemphigus vulgaris; Protocol; Rheumatoid arthritis; Rituximab

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADD ON THERAPY; B LYMPHOCYTE; BIOLOGICAL THERAPY; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG INFUSION; DRUG SAFETY; DRUG TARGETING; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAJOR CLINICAL STUDY; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; PEMPHIGUS VULGARIS; PNEUMOCYSTOSIS; RECURRENCE RISK; RELAPSE; REMISSION; REVIEW; SEPTICEMIA; STAPHYLOCOCCUS INFECTION; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; CHRONIC DISEASE; PATHOPHYSIOLOGY; PEMPHIGUS; RECURRENT DISEASE;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHRONIC DISEASE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; PEMPHIGUS; RECURRENCE; TREATMENT OUTCOME;

EID: 84923006467     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.12.002     Document Type: Review

References (104)

1. Gazit E., Loewenthal R. The immunogenetics of pemphigus vulgaris. Autoimmun Rev 2005 Jan, 4(1):16-20.
2. Sticherling M., Erfurt-Berge C. Autoimmune blistering diseases of the skin. Autoimmun Rev 2012, 11:226-230.
3. Meyer N., Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 2010, 9:A379-A382.
4. Hertl M., Veldman C. T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun Rev 2003, 2:278-283.
5. Sagi L., Sherer Y., Trau H., Shoenfeld Y. Pemphigus and infectious agents. Autoimmun Rev 2008, 8:33-35.
6. Oostingh G.J., Sitaru C., Kromminga A., et al. Autoreactive T cell responses in pemphigus and pemphigoid. Autoimmun Rev 2002, 1:267-272.
7. Bystryn J.C., Rudolph J.L. Pemphigus. Lancet 2005, 336:61-73.
8. Chams-Davatchi C., Valikhani M., Daneshpazhooh M., et al. Pemphigus: analysis of 1209 cases. Int J Dermatol 2005, 44:470-476.
9. Martin L.K., Werth V., Villanueva E., Segall J., Murrell D.F. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009, CD006263.
10. Martin L.K., Werth V.P., Villaneuva E.V., Murrell D.F. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011, 64:903-908.
11. Daniel B.S., Murrell D.F. Management of pemphigus. F1000Prime Rep 2014, 6:32.
12. Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol 2012, 30:78-83.
13. Ahmed A.R. Drug therapy of pemphigus vulgaris. G Ital Dermatol Venereol 2007, l42:391-408.
14. Kasperkiewicz M., Schmidt E., Zillikens D. Current therapy of the pemphigus group. Clin Dermatol 2012, 30:84-94.
15. Nigam R., Levitt J. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?. J Drugs Dermatol 2012, 11:622-625.
16. Yeh S.W., Sami N., Ahmed R.A. Treatment of pemphigus vulgaris: current and emerging options. Am J Clin Dermatol 2005, 6:327-342.
17. Perosa F., Favoino E., Caragnano M.A., Prete M., Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005, 4:526-531.
18. Dörner T., Isenberg D., Jayne D., et al. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 2009, 9:82-89.
19. Guzman Moreno R. B-cell depletion in autoimmune diseases. Advances in autoimmunity. Autoimmun Rev 2009, 8:585-590.
20. Grillo-López A.J., White C.A., Varns C., et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999, 26:66-73.
21. Smolen J.S., Keystone E.C., Emery P., Breedveld F.C., Betteridge N., Burmester G.R., et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:143-150.
22. Feldman R.J., Ahmed A.R. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol 2011, 7:529-541.
23. Murrell D.F., Dick S., Ahmed A.R., et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008, 58:1043-1046.
24. Kershenovich R., Hodak E., Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev 2014, 13:477-481.
25. Baum S., Sakka N., Artsi O., Trau H., Barzilai A. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev 2014, 13:482-489.
26. Schmidt E., Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010, 10:84-89.
27. Joly P., Mouquet H., Roujeau J.C., et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007, 357:545-552.
28. Cianchini G., Corona R., Frezzolini A., et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 2007, 143:1033-1038.
29. Antonucci A., Negosanti M., Tabanelli M., Varotti C. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J Dermatolog Treat 2007, 18:178-183.
30. Nagel A., Podstawa E., Eickmann M., et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009, 129:2202-2210.
31. Eming R., Nagel A., Wolff-Franke S., et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008, 128:2850-2858.
32. Schmidt, Hennig K., Mengede C., et al. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol 2009, 132:334-341.
33. Goh M.S., McCormack C., Dinh H.V., et al. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol 2007, 156:990-996.
34. Müller R., Hunzelmann N., Baur V., et al. Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris. Dermatol Res Pract 2010, 2010:321950.
35. Reguiai Z., Tabary T., Maizières M., Bernard P. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol 2012, 67:623-629.
36. Kim M.R., Kim H.C., Kim S.C. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients. Dermatology 2011, 223:182-188.
37. Gregoriou S., Giatrakou S., Theodoropoulos K., et al. Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial. Dermatology 2014, 228:158-165.
38. Lunardon L., Tsai K.J., Propert K.J., et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol 2012, 148:1031-1036.
39. Pfütze M., Eming R., Kneisel A., et al. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 2009, 218:237-245.
40. Balighi K., Daneshpazhooh M., Khezri S., et al. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol 2013, 52:862-867.
41. Colliou N., Picard D., Caillot F., et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med Mar 6 2013, 5:175ra30.
42. Salopek T.G., Logsetty S., Tredget E.E. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002, 47:785-788.
43. Cooper H.L., Healy E., Theaker J.M., et al. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol 2003, 28:366-368.
44. Virgolini L., Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case. Haematologica 2003, 88:ELT24.
45. Herrmann G., Hunzelmann N., Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003, 148:602-603.
46. España A., Fernández-Galar M., Lloret P., et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004, 50:974-976.
47. Morrison L.H. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004, 51:817-819.
48. Dupuy A., Viguier M., Bédane C., et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004, 140:91-96.
49. Wenzel J., Bauer R., Bieber T., Tüting T. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol 2005, 85:185-186.
50. Arin M.J., Engert A., Krieg T., Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005, 153:620-625.
51. Cecchi R., Gasperini U. Severe pemphigus vulgaris treated with rituximab (Mabthera). J Dermatol 2005 Oct, 32(10):862-864.
52. Niedermeier A., Wörl P., Barth S. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 2006, 16:266-270.
53. Rios-Fernández R., Gutierrez-Salmerón M.T., Callejas-Rubio J.L., et al. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol 2007 Dec, 157:1271-1273.
54. Esposito M., Capriotti E., Giunta A., et al. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol 2006, 86:87-89.
55. Marzano A.V., Fanoni D., Venegoni L., et al. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Expert Rev Clin Immunol 2008, 4:351-363.
56. Weger W., Aberer E. Treatment failure with rituximab in a patient with pemphigus vulgaris. J Eur Acad Dermatol Venereol 2008, 22:387-389.
57. Wollina U., Koch A., Hansel G. Rituximab therapy of recalcitrant bullous dermatoses. J Dermatol Case Rep 2008, 2:4-7.
58. Sorce M., Aricò M., Bongiorno M.R. Rituximab in refractory pemphigus vulgaris. Dermatol Ther 2008, 21(Suppl. 1):S6-S9.
59. Tournadre A., Amarger S., Joly P. Polymyositis and pemphigus vulgaris in a patient: successful treatment with rituximab. Joint Bone Spine 2008, 75:728-729.
60. Menezes N., Leite I., Tente D., et al. Pemphigus vulgaris-still a difficult disease to treat. Int J Dermatol 2010, 49:230-232.
61. Schmidt E., Herzog S., Bröcker E.B., et al. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005, 153:449-451.
62. Bomm L., Fracaroli T.S., Sodré J.L., et al. Off-label use of rituximab in dermatology: pemphigus treatment. An Bras Dermatol 2013, 88:676-678.
63. Kim J., Teye K., Koga H., et al. Successful single-cycle rituximab treatment in a patient with pemphigus vulgaris and squamous cell carcinoma of the tongue and IgG antibodies to desmocollins. J Am Acad Dermatol 2013, 69:e26-e27.
64. Corral I.S., Freitas T.H., Aquino R.T. Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab. An Bras Dermatol 2013, 88:639-642.
65. Fuertes I., Guilabert A., Mascaró J.M., Iranzo P. Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature. Dermatology 2010, 221:13-16.
66. Schmidt E., Seitz C.S., Benoit S. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007, 156:352-356.
67. Gregoriou S., Koutsoukou X.A., Panayotides I., et al. Pemphigus vulgaris of the epiglottis successfully treated with rituximab. J Eur Acad Dermatol Venereol 2014, [Epub ahead of print].
68. Kasperkiewicz M., Shimanovich I., Ludwig R.J., Rose, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2010, 65:552-558.
69. Horváth B., Huizinga J., Pas H.H., et al. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012, 166:405-412.
70. Kanwar A.J., Tsuruta D., Vinay K., et al. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol 2013, 27:e17-e23.
71. Matsukura S., Knowles S.R., Walsh S., Shear N.H. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. Arch Dermatol 2012, 148:734-739.
72. Cianchini G., Lupi F., Masini C., et al. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol 2012, 67:617-622.
73. Kasperkiewicz M., Shimanovich I., Meier M., et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 2012, 166:154-160.
74. Behzad M., Möbs C., Kneisel A. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 2012, 166:844-852.
75. Kanwar A.J., Vinay K., Sawatkar G.U., et al. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol 2014, 170:1341-1349.
76. Heelan K., Al-Mohammedi F., Smith M.J., et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol 2014, 150:703-708.
77. Cho H.H., Jin S.P., Chung J.H. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities. J Eur Acad Dermatol Venereol. 2013, 28:186-191.
78. Kim J.H., Kim Y.H., Kim M.R., Kim S.C. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol 2011, 165:646-651.
79. Cho Y.T., Lee F.Y., Chu C.Y., Wang L.F. First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus. Acta Derm Venereol 2014, 94:472-473.
80. Craythorne E.E., Mufti G., DuVivier A.W. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2011, 65:1064-1065.
81. Shimanovich I., Nitschke M., Rose C., et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008, 158:382-388.
82. Belgi A.S., Azeez M., Hoyle C., Williams R.E. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol 2006, 31:143.
83. Barrera M.V., Mendiola M.V., Bosch R.J., Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. J Dermatolog Treat 2007, 18:312-314.
84. Faurschou A., Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol 2008, 47:292-294.
85. Craythorne E., du Viver A., Mufti G.J., Warnakulasuriya S. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med 2011, 40:616-620.
86. Kong H.H., Prose N.S., Ware R.E., Hall R.P. Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol 2005, 2:461-464.
87. Kanwar A.J., Sawatkar G.U., Vinay K., Hashimoto T. Childhood pemphigus vulgaris successfully treated with rituximab. Indian J Dermatol Venereol Leprol 2012, 78:632-634.
88. Diamanti A.P., Rosado M.M., Carsetti R., Valesini G. B cells in SLE: different biological drugs for different pathogenic mechanisms. Autoimmun Rev 2007, 7:143-148.
89. Kamal A., Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: A review. Autoimmun Rev. 2014, 13:1094-1101.
90. Doria A., Putterman C., Sarzi-Puttini P., Szekanecz Z., Shoenfeld Y. Controversies in rheumatism and autoimmunity. Autoimmun Rev 2012, 11:555-557.
91. van Vollenhoven R.F. Rituximab-shadow, illusion or light?. Autoimmun Rev 2012, 11:563-567.
92. Isenberg D.A. Rituximab-it was the best of times, it was the worst of times. Autoimmun Rev 2012, 11:790-791.
93. Kattah A.G., Fervenza F.C., Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev 2013, 12:854-859.
94. Atzeni F., Benucci M., Sallì S., et al. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 2013, 12:575-579.
95. Caporali R., Caprioli M., Bobbio-Pallavicini F. Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev 2009, 8:591-594.
96. Ferri C., Cacoub P., Mazzaro C. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011, 11:48-55.
97. Berman H., Rodríguez-Pintó I., Cervera R. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013, 12:1085-1090.
98. Khattri S., Zandman-Goddard G., Peeva E. B-cell directed therapies in antiphospholipid antibody syndrome-new directions based on murine and human data. Autoimmun Rev 2012, 11:717-722.
99. Cornec D., Avouac J., Youinou P., Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev 2009, 8:515-519.
100. Levy R., Mahévas M., Galicier L. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Autoimmun Rev 2014, 13:1055-1063.
101. Shetty S., Ahmed A.R. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity 2013, 46:487-496.
102. Ahmed A.R., Spigelman Z., Cavacini L.A., Posner M.R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006, 355:1772-1779.
103. Leuci S., Levine D., Zhang J., Razzaque Ahmed A. Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells. G Ital Dermatol Venereol 2009, 144:379-409.
104. Mohrbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther 2005, 7(Suppl. 3):S19-S25.